PMID- 12555874
OWN - NLM
STAT- MEDLINE
DCOM- 20030415
LR  - 20190916
IS  - 0936-6555 (Print)
IS  - 0936-6555 (Linking)
VI  - 14
IP  - 5
DP  - 2002 Oct
TI  - Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin 
      and vinorelbine followed by CHART radiotherapy for locally advanced non-small 
      cell lung cancer.
PG  - 361-6
AB  - In an attempt to evaluate the safety and efficacy of chemotherapy and continuous 
      hyperfractionated radiotherapy (CHART) for non small cell lung cancer (NSCLC), a 
      dose-escalation study was initiated, in which patients were treated with a 
      combination of Vinorelbine and Carboplatin chemotherapy and CHART radiotherapy. 
      The first cohort of 3 patients were treated with induction chemotherapy 
      (Vinorelbine 30mg/m2 weeks 1,2,4 and 5, and Carboplatin, AUC = 5mg/ml/min weeks 1 
      and 4) followed by CHART radiotherapy (5400cGy in 36 fractions in 12 days on 
      weeks 7 and 8). It was intended to then treat subsequent cohorts of patients with 
      increasing doses of chemotherapy concomitantly with CHART, but unfortunately 2 of 
      the first 3 patients both developed respiratory failure due to widespread 
      pulmonary fibrosis, and died 7 and 9 weeks after completing treatment. At this 
      point the study was closed. The combination of chemotherapy and CHART for NSCLC 
      may have significant pulmonary toxicity and this potentially serious adverse 
      effect needs to be carefully considered when planning future research studies is 
      this area.
FAU - Kirkbride, Peter
AU  - Kirkbride P
AD  - Department of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, UK.
FAU - Hatton, Mathew
AU  - Hatton M
FAU - Lorigan, Paul
AU  - Lorigan P
FAU - Joyce, Patrick
AU  - Joyce P
FAU - Fisher, Patricia
AU  - Fisher P
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Clin Oncol (R Coll Radiol)
JT  - Clinical oncology (Royal College of Radiologists (Great Britain))
JID - 9002902
RN  - 5V9KLZ54CY (Vinblastine)
RN  - BG3F62OND5 (Carboplatin)
RN  - Q6C979R91Y (Vinorelbine)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carboplatin/administration & dosage
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/*radiotherapy
MH  - Clinical Trials as Topic
MH  - Combined Modality Therapy
MH  - Dose Fractionation, Radiation
MH  - Dose-Response Relationship, Radiation
MH  - Fatal Outcome
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology/*radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Pulmonary Fibrosis/*etiology/pathology
MH  - Vinblastine/administration & dosage/*analogs & derivatives
MH  - Vinorelbine
EDAT- 2003/01/31 04:00
MHDA- 2003/04/16 05:00
CRDT- 2003/01/31 04:00
PHST- 2003/01/31 04:00 [pubmed]
PHST- 2003/04/16 05:00 [medline]
PHST- 2003/01/31 04:00 [entrez]
AID - S0936-6555(02)90119-6 [pii]
AID - 10.1053/clon.2002.0119 [doi]
PST - ppublish
SO  - Clin Oncol (R Coll Radiol). 2002 Oct;14(5):361-6. doi: 10.1053/clon.2002.0119.